Active substance
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| HUMULIN-R-REGULAR 100 U-ML | 100 IU/ml | Solution for injection · Subcutaneous use | 1 Vial | SAR 53.55 | Biological · Prescription | Eli Lilly and Company | Valid |
| INSULATARD | 100 IU/ml | Suspension for injection · Subcutaneous use | 1 Vial | SAR 65.00 | Biological · Prescription | NOVO NORDISK | Valid |
| HUMULIN-L LENTE 100 U-ML | 100 IU/ml | Suspension for injection · Subcutaneous use | 1 Vial | SAR 53.55 | Biological · OTC | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
| HUMULIN-R 100U-ML CARTRIDGE | 100 IU/ml | Solution for injection · Subcutaneous use | 5 Cartridge | SAR 93.70 | Biological · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
| ULTRATARD HM 100 I.U. VIAL | 100 IU/ml | Suspension for injection · Subcutaneous use | 1 Vial | SAR 65.00 | Biological · Prescription | NOVO NORDISK | Withdrawn by MAH · Not Marketed |
BRADYCARDIA; DIABETES MELLITUS TYPE 1; DIABETES MELLITUS TYPE 2; DIABETIC KETOACIDOSIS; HYPERKALEMIA
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| HUMULIN R KWIKPEN | 1500 UNITS/3ML (500 UNITS/ML) | solution · subcutaneous | LILLY | Prescription | 28 Oct 1982 |
| HUMULIN R | 10000 UNITS/20ML (500 UNITS/ML) | solution · subcutaneous | LILLY | Prescription | 28 Oct 1982 |
| MYXREDLIN | 100 UNITS/100ML (1 UNIT/ML) | solution · intravenous | BAXTER HLTHCARE CORP | Prescription | 20 Jun 2019 |
Diabetes mellitus where treatment with insulin is required. Insuman Rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and postoperative stabilisation in patients with diabetes mellitus.
Treatment of diabetes mellitus.
Treatment of diabetes mellitus.
Treatment of diabetes mellitus.
Treatment of diabetes mellitus.
Treatment of diabetes mellitus.
treatment of diabetes mellitus
Treatment of diabetes mellitus
treatment of diabetes mellitus
Treatment of diabetes
Treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis
Treatment of diabetes mellitus.
Treatment of diabetes mellitus.
Treatment of diabetes mellitus.
EXUBERA is indicated for the treatment of adult patients with type 2 diabetes mellitus notadequately controlled with oral antidiabetic agents and requiring insulin therapy.EXUBERA is also indicated for the treatment of adult patients with type 1 diabetes mellitus, inaddition to long or intermediate acting subcutaneous insulin, for whom the potential benefits ofadding inhaled insulin outweigh the potential safety concerns (see section 4.4).
Diabetes mellitus where treatment with insulin is required. Insulin Human Winthrop Rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and postoperative stabilisation in patients with diabetes mellitus.
Inpremzia is indicated for the treatment of diabetes mellitus.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.